Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Fig. 2

Proportion of patients maintaining a mean arterial pressure >60 mmHg without any open-label norepinephrine support at the indicated time points. The difference between 2.5 ng/kg/minute and placebo was statistically significant (p < 0.01) at 24 h. Results are means, with bars indicating SD

Back to article page

Critical Care

ISSN: 1364-8535